SCHEDULE: Lytton and Foundation Update AYTU Biopharma Stake
Beneficial Ownership Report
Laurence W. Lytton and Lytton-Kambara Foundation updated their passive beneficial ownership in AYTU Biopharma, Inc., reporting stakes of 9.99% and 8.8% respectively.
Summary
- Laurence W. Lytton beneficially owns 1,071,351 shares of AYTU Biopharma, Inc. common stock, representing 9.99% of the class.
- Lytton's ownership includes 535,318 shares of common stock and warrants to purchase 731,666 shares, subject to a 9.99% beneficial ownership limitation.
- Lytton-Kambara Foundation beneficially owns 895,528 shares of AYTU Biopharma, Inc. common stock, representing 8.8% of the class.
- The Foundation's ownership includes 497,218 shares of common stock and warrants to purchase 398,310 shares, also subject to a 9.99% beneficial ownership limitation.
- The percentages are based on 10,188,208 shares of Common Stock outstanding as of November 1, 2025, as reported in the Issuer's Form 10-Q for the quarterly period ended September 30, 2025.
- Both reporting persons have certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of AYTU Biopharma, Inc.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a standard beneficial ownership disclosure (Schedule 13G Amendment No. 2) indicating passive investment without any stated intent to influence control or significant operational changes.
Positives
- Increased transparency regarding significant passive ownership stakes in AYTU Biopharma, Inc.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive investors holding more than 5% of a company's stock, providing transparency on significant ownership stakes without indicating an intent to influence control. This filing is specific to AYTU Biopharma and does not directly reflect broader industry trends.
Related Party Transactions
- Laurence W. Lytton and Lytton-Kambara Foundation have entered into an agreement to jointly file Schedule 13D or 13G and Forms 3, 4, or 5, with Laurence W. Lytton appointed as the agent and attorney-in-fact for such filings.
Stakeholder Impact
- Shareholders gain transparency regarding significant passive ownership stakes held by Laurence W. Lytton and Lytton-Kambara Foundation.
Key Dates
| Date | Description |
|---|---|
| 2025-11-01 | Date as of which 10,188,208 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-12-31 | Date of event which required the filing of this statement. |
| 2026-02-17 | Date of signing and filing of the Schedule 13G Amendment No. 2. |
Keywords
AYTU Biopharma, Beneficial Ownership, Schedule 13G, Laurence W. Lytton, Lytton-Kambara Foundation, Common Stock, Warrants, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.